Propantheline bromide Rx
Generic Name and Formulations:
Propantheline bromide 15mg; tabs.
Roxane Laboratories, Inc.
Indications for Propantheline bromide:
Adjunctive therapy in the treatment of peptic ulcer.
15mg taken 30 minutes before each meal and 30mg at bedtime. Total daily dose: 75mg.
Glaucoma. GI obstruction (eg, pyloroduodenal stenosis, achalasia, paralytic ileus). GU obstruction (eg, bladder-neck obstruction due to prostatic hypertrophy). Intestinal atony of elderly or debilitated. Severe ulcerative colitis. Toxic megacolon. Unstable cardiovascular adjustment in acute hemorrhage. Myasthenia gravis.
High environmental temperature. Monitor for diarrhea; may be symptom of incomplete intestinal obstruction. Heart disease. CHF. Cardiac tachyarrhythmias. Hypertension. Hiatal hernia associated with reflux esophagitis. Autonomic neuropathy. Hepatic or renal disease. Hyperthyroidism. Elderly. Pregnancy (Cat.C). Nursing mothers.
Additive anticholinergic effects with concomitant belladonna alkaloids, narcotic analgesics (eg, meperidine), Class I antiarrhythmics (eg, disopyramide, procainamide, quinidine), antihistamines, phenothiazines (may potentiated sedative effects), tricyclic antidepressants, other anticholinergics. Increased intraocular pressure with concomitant corticosteroids. May potentiate slow-dissolving digoxin tablets; use rapidly-dissolving digoxin tablets instead.
Drying of salivary secretions, decreased sweating, ophthalmic effects (eg, blurred vision, mydriasis, cycloplegia, increased ocular tension), urinary hesitancy and retention, tachycardia, palpitations, loss of sense of taste, headache, nervousness, mental confusion, drowsiness, weakness, dizziness, insomnia, GI upset, constipation, bloating, impotence, lactation suppression, allergic reactions.
Formerly known under the brand name Pro-Banthine.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC